International asthma guidelines recommend increasing the dose of ICS or adding leukotriene modifiers or the use of long-acting inhaled beta2 agonists (LABAs) in combination with inhaled corticosteroids (ICS) when uncontrolled asthma occur in adult and children in treatment with low-dose inhaled corticosteroids. However, in children, the effects of this last treatment option are unclear because there are few studies on the efficacy and safety of these drugs in pediatric age. Furthermore, salmeterol is licensed for use in children over 4 years and formoterol in children of more than 6 years. Finally, recent data provides evidence that repeated bronchoconstriction induces epithelial cells stress that may lead to remodeling and these findings may have potential implications for asthma management, particularly for LABAs treatment in the future.